Resumo

KHOSRAVI SHAHI, P. et al. Efficency of bortezomib and dexamethasone in relapsed multiple myeloma treatment: retrospective study in consecutive cases. An. Med. Interna (Madrid) [online]. 2008, vol.25, n.2, pp.73-77. ISSN 0212-7199.

Introduction: Multiple myeloma (MM) is a plasm-cell neoplasm, that is characterized by a monoclonal protein in the serum or urine. Bortezomib is an efficacy drug for the second line treatment of MM. Patients and method: We conducted a retrospective study of 21 consecutive cases with refractory MM treated with bortezomib and dexame-thasone as second line therapy, with the objective of analyzing the overall response rate (primary end point), the progression-free survival (PFS), the overall survival (OS), the duration of response (DR) and toxicity profile (second end points). Results: In our study we found an overall response rate of 70%. With a median follow-up of 15 months, we had a median PFS of 12 months (95% CI: 2-21 months), with a median OS of 17 months (95% CI: 2-32 months), and a median DR of 9 months (95% CI: 5-13 months). Fourty-seven percent of patients had neuropathy, the 33% thrombocytopenia, 13.33% anemia and 26.66% diarrhea. Conclusions: The combination of bortezomib and dexamethasone is an effective and safe treatment in second line of refractory MM, with a manageable toxicity.

Palavras-chave : Bortezomib; Dexamethasone; Progression-free survival; Myeloma; Response rate.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )